Evidence map›Paper›PMID 10603396›Full record

ArticleInfection and immunity2000

Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro.

M O Eze, L Yuan, R M Crawford, C M Paranavitana, T L Hadfield, A K Bhattacharjee, R L Warren, D L Hoover

Abstract read
In one paragraph

Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Low Interleukin-12 Levels concerning Severe Malaria: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  2. Article
  3. A genome-wide CRISPR screen defines host determinants of earlybioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Microorganisms · 2022
    Review
  6. Article
  7. The Role of Neutrophils in Brucellosis.Microbiology and molecular biology reviews : MMBR · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Article
  15. Article
  16. Article
  17. Host interferon-γ inducible protein contributes to Brucella survival.Frontiers in cellular and infection microbiology · 2012
    Article
  18. Article
  19. Article
  20. A B lymphocyte mitogen is a Brucella abortus virulence factor required for persistent infection.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M O EzeDepartment of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100, USA.
L Yuan
R M Crawford
C M Paranavitana
T L Hadfield
A K Bhattacharjee
R L Warren
D L Hoover
Walter Reed Army Institute of Research · USArmed Forces Institute of Pathology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entry of opsonized pathogens into phagocytes may benefit or, paradoxically, harm the host. Opsonization may trigger antimicrobial mechanisms such as reactive oxygen or nitric oxide (NO) production but may also provide a safe haven for intracellular replication. Brucellae are natural intramacrophage pathogens of rodents, ruminants, dogs, marine mammals, and humans. We evaluated the role of opsonins in Brucella-macrophage interactions by challenging cultured murine peritoneal macrophages with Brucella melitensis 16M treated with complement- and/or antibody-rich serum. Mouse serum rich in antibody against Brucella lipopolysaccharide (LPS) (aLPS) and human complement-rich serum (HCS) each enhanced the macrophage uptake of brucellae. Combinations of suboptimal levels of aLPS (0. 01%) and HCS (2%) synergistically enhanced uptake. The intracellular fate of ingested bacteria was evaluated with an optimal concentration of gentamicin (2 microg/ml) to control extracellular growth but not kill intracellular bacteria. Bacteria opsonized with aLPS and/or HCS grew equally well inside macrophages in the absence of gamma interferon (IFN-gamma). Macrophage activation with IFN-gamma inhibited replication of both opsonized and nonopsonized brucellae but was less effective in inhibiting replication of nonopsonized bacteria. IFN-gamma treatment of macrophages with opsonized or nonopsonized bacteria enhanced NO production, which was blocked by N(G)-monomethyl L-arginine (MMLA), an NO synthesis inhibitor. MMLA also partially blocked IFN-gamma-mediated bacterial growth inhibition. These studies suggest that primary murine macrophages have limited ability to control infection with B. melitensis, even when activated by IFN-gamma in the presence of highly opsonic concentrations of antibody and complement. Additional cellular immune responses, e.g., those mediated by cytotoxic T cells, may play more important roles in the control of murine brucellosis.

Indexed as

AnimalsAntibodies, BacterialBrucella melitensisComplement System ProteinsDogsFemaleGentamicinsHumansInterferon-gammaIn Vitro TechniquesMacrophage ActivationMacrophages, PeritonealMiceMice, Inbred BALB CNitric OxideOpsonin ProteinsAntibodies, BacterialComplement System ProteinsGentamicinsInterferon-gammaNitric OxideOpsonin ProteinsRecombinant Proteins

Identifiers

PMID10603396
PMCPMC97129
OpenAlexW2157683720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.